Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment
Background: Ticagrelor is a first-line drug for the treatment of acute ST elevation myocardial infarction (STEMI). However, approximately 20% STEMI patients taking ticagrelor exhibited a delayed response and the mechanism was still unclear. Methods: To explore the mechanism of the poor response of t...
Main Authors: | Xi Zhang, Xiaolin Zhang, Fangnian Tong, Yi Cai, Yujie Zhang, Haixu Song, Xiaoxiang Tian, Chenghui Yan, Yaling Han |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2022-03-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/70240 |
Similar Items
-
Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
by: Piotr Adamski, et al.
Published: (2022-02-01) -
Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study
by: Giuseppe Gargiulo, et al.
Published: (2024-02-01) -
Efficacy and safety of cangrelor as compared to ticagrelor in patients with ST-elevated myocardial infarction (STEMI): a systematic review and meta-analysis
by: Subhro Chakraborty, et al.
Published: (2024-04-01) -
Clinical outcomes with the use of ticagrelor or clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction – A prospective observational study
by: Bibek Agarwal, et al.
Published: (2022-01-01) -
Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
by: Thomas W. Johnson, et al.
Published: (2020-12-01)